Objectives The aim of this study was to understand the impact of attenuated plaque on distal embolization during stent implantation in patients with acute myocardial infarction (AMI).
Percutaneous coronary intervention (PCI) with stent implantation is often performed to treat patients with acute myocardial infarction (AMI). However, PCI fails to achieve Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 in 12% to 30% of cases, mainly because of the no-reflow phenomenon that is associated with poor functional and clinical outcomes (1) (2) (3) (4) (5) . Retrospective intravascular ultrasound (IVUS) studies have shown that attenuated plaque (hypoechoic or mixed atheroma with ultrasound attenuation but without calcification) is common in acute coronary syndromes and is associated with a high rate of no-reflow or transient deterioration in coronary flow during PCI (6, 7) . The aim of the present study is to use the data from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial to evaluate the impact of attenuated plaque on noreflow in patients with AMI undergoing primary stent implantation.
Methods
Study population. The HORI-ZONS-AMI trial was a dual-arm, factorial, randomized trial in patients with ST-segment elevation myocardial infarction (STEMI). There were 2 randomization steps: 1) unfractionated heparin plus routine glycoprotein IIb/IIIa inhibition versus bivalirudin alone (1:1 randomization); and 2) paclitaxeleluting TAXUS stents versus bare metal EXPRESS stents (Boston Scientific, Natick, Massachusetts) (3:1 randomization). A formal IVUS substudy enrolled 464 patients with baseline and 13-month follow-up imaging at 36 centers. The primary prespecified endpoint of the IVUS substudy has been reported previously (8) .
This study was approved by the institutional review boards of the institutions in which the procedures were performed. Written informed consent was obtained from all patients before cardiac catheterization.
Clinical data were collected and included risk factors, left ventricular ejection fraction (LVEF) (evaluated by left ventriculography), and creatine kinase-myocardial band (CK-MB) levels. Quantitative and qualitative coronary angiography. Coronary angiograms at baseline and immediately after PCI were performed in at least 2 orthogonal views after intracoronary nitroglycerin. Angiograms were analyzed at the Angiographic Core Laboratory of the Cardiovascular Research Foundation (New York, New York), which was blinded to the clinical and IVUS findings with the CMS-GFT algorithm (MEDIS, Leiden, the Netherlands). Minimum lumen diameter (MLD) and mean reference vessel diameter (RVD), obtained by averaging 5-mm segments proximal and distal to the targetlesion, were used to calculate diameter stenosis: ([1 Ϫ MLD/ RVD] ϫ 100%). Angiographic coronary blood flow was assessed at baseline and after PCI on the basis of TIMI flow grade (9) and corrected Thrombolysis In Myocardial infarction frame count (CTFC) (10) . No-reflow was defined as final TIMI flow grade 0 and 1 or 2 in the absence of mechanical obstruction. Qualitative analysis was done with standard methods (11) . Presence or absence of intracoronary thrombus (hazy, globular filling defect, or total occlusion) and calcification were evaluated. IVUS imaging and analysis. The ϭ external elastic membrane Ϫ lumen) cross-sectional areas every 1 mm. Qualitative analysis included: 1) attenuation behind the plaque in the absence of calcification; 2) intra-stent plaque and/or thrombus protrusion (IVUS cannot reliably differentiate between plaque vs. thrombus that protrudes through stent struts); 3) intra-plaque echolucent zone (absence of ultrasound signal within the plaque); and 4) edge dissection (tangential tear in the plaque at the stent edge).
As previously reported, a mean attenuation score was created by measuring the angle of attenuation each 1 mm, scoring the angle as 1, 2, 3, or 4 points when the attenuation angle was Ͻ90°, 90°to 180°, 180°to 270°, or 270°to 360°, respectively; summing the scores to create an overall attenuation score; and finally, normalizing for analysis length ( Fig. 1 ) (12) . Plaque without attenuation was scored as 0 points. The presence of attenuation and the mean attenuation scores were analyzed by 2 independent, experienced observers (X.W. and A.M.), and consensus interpretation was included in the subsequent analysis.
Intraobserver and interobserver variability and reliability analysis.
All lesions were analyzed 3 months apart to assess intraobserver and interobserver variability in the identification of attenuated plaque; both intraobserver (kappa ϭ 0.96) and interobserver (kappa ϭ 0.94) variability yielded good concordance. To assess the reproducibility of the mean attenuation score, 100 consecutive lesions were analyzed by 2 observers (X.W. and A.M.); the difference in the mean attenuation score after stenting was 0.08 Ϯ 0.23 points, and the intraclass correlation coefficient for repeated measurement was 0.98.
Although only post-stent IVUS was pre-specified in the HORIZONS protocol, pre-PCI IVUS was performed in 40 patients at the discretion of the operator. We used images from these 40 patients to compare attenuation detection and mean attenuation score calculation between pre-and post-PCI IVUS studies. In these 40 lesions with both pre-and poststenting IVUS, there were 29 attenuated plaques; there was complete agreement between the pre-stent and post-stent assessment of the presence of IVUS attenuation. The difference in the calculated mean attenuation score was 0.07 Ϯ 0.12 points. Intraclass correlation coefficient comparing preversus post-stenting attenuation was 0.99. An example is shown in Figure 2 . Statistical analysis. Statistical analysis was performed with SAS software (version 9.1, SAS Institute, Inc., Cary, North Carolina). Categorical variables were compared with chisquare statistics or Fisher exact test. Continuous variables were compared with Wilcoxon rank-sum test and displayed as median (interquartile range). The cutoff of mean attenuation score was calculated by receiver-operator characteristic curve to predict no-reflow. The optimal cut-point was selected when the highest sum of sensitivity and specificity was available. We conducted a stepwise multivariate logistic regression analysis to identify independent predictors of no-reflow. The Attenuation score was 1, 2, 3, or 4 points when the attenuation angle was Ͻ90°, 90°to 180°, 180°to 270°, or 270°to 360°, respectively. In this picture, attenuation angle was 120°; therefore, attenuation score was 2 points.
grafts, 38 lesions in noninfarct-related arteries, and 16 lesions with unreliable pullback or zoom or gain not appropriate to evaluate attenuated plaque. Eventually, 364 de novo infarct-related coronary artery lesions in 364 patients were included. Clinical characteristics. Overall, 78.8% (287) were men; the median patient age was 60.3 (51.3 to 68.9) years; 39.0% (n ϭ 142) had infarct-related left anterior descending coronary artery (LAD) lesions; pre-intervention angiographic thrombus was present in 75.0% (n ϭ 273); 73.1% (n ϭ 266) had a pre-PCI TIMI flow grade Յ2; and pre-PCI LVEF was 61.0% (51.4% to 67.6%). As shown in Table 1 , there were no statistically significant differences between patients with and without no-reflow except: 1) no-reflow was associated with lower CK-MB; 2) patients with no-reflow had higher CK-MB before and after PCI; and 3) there were fewer current smokers in the no-reflow group. Angiographic and procedural findings. As shown in Table 2 , patients with no-reflow more often had PCI of an LAD than a non-LAD lesion (59.5% vs. 36.7%, p ϭ 0.026). Baseline angiographic thrombus was more frequent in patients with versus without no-reflow (89.2% vs. 74.1%, p ϭ 0.043). Pre-PCI TIMI flow grade 0 to 2 was more common in patients with versus without no-reflow (86.5% vs. 71.2%, p ϭ 0.047); similarly, pre-PCI CTFC was higher in no-reflow patients A and B were longitudinal sections through same lesion before and after percutaneous coronary intervention (PCI). Mean attenuation score was analyzed by measuring the attenuation angle each 1 mm (cross-section of lesion before PCI: A0 to A5; cross-section of lesion after PCI: B0 to B5), then summing the scores, and normalizing for analysis length. A0 and B0 were bifurcation markers. Pre-PCI (A) attenuation angles of slices A1 to A5 were 40°, 55°, 95°, 105°, and 60°, respectively. The corresponding attenuation scores were 1, 1, 2, 2, and 1 points; the mean attenuation score was 7/4.8 ϭ 1.5. Post-PCI (B) attenuation angles of B1 to B5 were 45°, 55°, 105°, 110°, and 55°, respectively; the corresponding attenuation score were 1, 1, 2, 2, and 1 points, yielding a mean attenuation score of 7/4.8 ϭ 1.5. N T I O N S , V O L . 4 , N O . 5 , 2 0 1 1   M A Y 2 0 1 1 : 4 
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Grayscale IVUS image analysis. As summarized in Table 3 , there were no statistically significant quantitative differences between patients with and those without no-reflow. The frequency of plaque/thrombosis protrusion and echolucent plaque was also similar between the 2 groups. Attenuated plaque and no-reflow. Overall, 78.0% (n ϭ 284) of the patients had attenuated plaques, and 10.2% (n ϭ 37) had no-reflow. There were 284 (78.0%) attenuated plaques in the stented segment and 122 (33.5%) in the proximal or distal unstented reference vessels, 115 of which (94.3%) were located both within the stented segment and in the reference segment, whereas 7 (5.7%) were located only in the reference segments (p Ͻ 0.001).
The mean attenuation score was significantly higher (2. In 284 patients with attenuated plaques, no-reflow was associated with older patient age (66. Independent predictors of no-reflow included mean attenuation score Ն2 (odds ratio: 6.586, 95% confidence interval: 2.680 to 16.188, p Ͻ 0.001) and angiographic thrombosis before PCI (odds ratio: ϭ 9.143, 95% confidence interval: 1.182 to 70.732, p ϭ 0.034). However, mean attenuation score Ն2 points had nearly 10 times the likelihood of no-reflow as mean attenuation score Ͻ2 points. Baseline TIMI flow grade and CTFC, target lesion length, infarct-related LAD lesion location, and echolucent plaque identified by IVUS did not correlate with no-reflow in this model.
Discussion
The major findings in the present study were that attenuated plaque was present in three-quarters of patients with Values are median (interquartile range) or n (%).
BMI ϭ body mass index; CAD ϭ coronary artery disease; CK-MB ϭ creatine kinase-myocardial band; LVEF ϭ left ventricular ejection fraction; PCI ϭ percutaneous coronary intervention. STEMI. Because attenuated plaque was present in such a large percentage of STEMI patients, its mere presence did not predict no-reflow. Instead, the larger the attenuated plaque, the greater the likelihood of no-reflow; a mean attenuation score Ն2 points (attenuation angle Ն90°, indicative of a large, diffuse attenuated plaque) best-predicted no-reflow (sensitivity of 81.5%, specificity of 80.5%, area under the receiveroperator characteristic curve of 0.883). No-reflow is related to capillary occlusion and microemboli to coronary resistance vessels (13-16). The capillary structure becomes disorganized in the no-reflow zone, because of endothelial swelling, tissue compression, myocyte edema, and neutrophil infiltration (17, 18) . This usually results from a large AMI but can be worsened by reperfusion. No-reflow is also attributed to thrombus and/or plaque embolization during PCI (19 -22) . These plaque components (including platelet-fibrin complex, macrophages, and cholesterol crystals) provoke arteriole spasm leading to further microvascular congestion, thrombosis, and sluggish coronary flow.
Previous studies have demonstrated that a greater pre-PCI plaque burden and a decreased plaque volume during PCI were related to CK-MB elevation after PCI (23-25) . However, not only the size of the plaque but its composition is important in the pathogenesis of no-reflow. Specific grayscale IVUS plaque characteristics that have predicted no-reflow or CK-MB elevation after PCI have included a lipid pool-like image, positive remodeling, intracoronary mural thrombus, and now attenuated plaque (6, 19, 21, 26) . However, grayscale IVUS has only a limited ability to assess atherosclerotic plaque composition. Analysis of radiofrequency ultrasound backscatter signals known as integrated backscatter (IB)-IVUS or virtual histology (VH)-IVUS have been developed to improve on these limitations of grayscale IVUS. We have recently reported the strong relationship between attenuated plaque (grayscale IVUS) and a large amount of necrotic core indicative of a fibroatheroma (VH-IVUS) (27) . This relationship is supported by histopathological studies demonstrating that attenuated plaque is composed of microcalcifications and cholesterol crystals (28, 29) . Acute coronary syndromes are most often caused by thrombosis superimposed on rupture of a thin-cap fibroatheroma containing a large necrotic core (30, 31) . Both IB-IVUS and VH-IVUS studies have suggested that lipidrich plaque (IB-IVUS) or necrotic core-rich plaque (VH-IVUS) are associated with no-reflow (32) (33) (34) (35) . Thus, attenuated plaques represent a large amount of necrotic core containing fragile tissues such as lipid deposition with foam cells, cholesterol crystals, and microcalcifications that are easily embolized by mechanical fragmentation during coronary stenting.
However, the current study also shows that attenuated plaques are present in three-quarters of infarct-related lesions of STEMI patients. Thus, it is the size of the attenuated plaque and not its mere presence that is related to no-reflow. In a practical way, the current study suggests that culprit lesions containing a mean attenuation angle Ͼ90°have a higher risk of no-reflow. However, attenuation varies significantly over the length of the lesion. In the majority of infarct-related lesions, the arc of attenuated plaque is Ͼ180°( and sometimes circumferential) in the middle of the lesion and tapers closer to the reference segments. Therefore, the calculation of a mean attenuation score takes into account the severity of attenuation at its worst cross-section as well as its distribution (12, 30) . However, the frequency of attenuated plaque is higher in the current study than is reported by Lee et al. (6) but similar to the study by Okura et al. (7) . The differences are not entirely clear, although patient selection might be an important explanation.
In the current analysis, attenuated plaque was also associated with reduced coronary flow before PCI; the incidence of pre-PCI TIMI flow grade 0/1 was 77.4% in patients with attenuated plaque versus 56.8% in patients without attenuated plaque. Previous studies have shown that spontaneous distal embolism of thrombus or atheromatous gruel from the epicardial culprit lesion was common in acute coronary syndromes and might be further triggered by PCI (36,37). The current study extends these previous observations to Values are median (interquartile range) or n (%). *Average of proximal and distal (most normallooking) reference sites. †Focal stent expansion was calculated as minimum stent area (MSA) divided by average reference lumen cross-sectional area (CSA); diffuse stent expansion was calculated as mean stent area divided by average reference lumen CSA.
EEM ϭ external elastic membrane; IVUS ϭ intravascular ultrasound; MLA ϭ minimum lumen area; PϩM ϭ plaque ϩ media. suggest that large attenuated plaques might be more likely to embolize spontaneously before PCI as well as after balloon dilation and stent implantation. Study limitations. This was a retrospective analysis. However, data were collected prospectively by independent monitors at each site. In most patients, IVUS was only performed after stenting (according to the established protocol). However, in the subset of patients with both preand post-stent IVUS, there were no significant differences in the presence or amount of attenuated plaque comparing pre-versus post-stenting studies; and reliability analysis showed excellent repeat measurements. The number of variables included in our multivariate logistic regression analysis might lead to overfitting, due to the low number of events (n ϭ 37). However the final model is parsimonious, because only 2 variables were selected. Finally, we did not assess the amount of attenuated plaque, per se, but the attenuation angle. The pre-versus post-stent comparison in the current analysis indicates that the angle of attenuation does not change, even though plaque was embolized as indicated by the CK-MB changes (in the current study) and changes in plaque mass reported in previous studies (7, 38) .
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Conclusions
Attenuated plaque is present in three-quarters of patients with AMI. The extent of the attenuation rather than its mere presence is strongly correlated with no-reflow; the larger the attenuated plaque, the greater the likelihood of no-reflow. 
